Cited 13 time in
Impact of malignancy on Clostridium difficile infection
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chung, Min Sung | - |
| dc.contributor.author | Kim, Ji eun | - |
| dc.contributor.author | Kang, Jung Oak | - |
| dc.contributor.author | Pai, Hyunjoo | - |
| dc.date.accessioned | 2021-07-30T05:33:53Z | - |
| dc.date.available | 2021-07-30T05:33:53Z | - |
| dc.date.issued | 2016-11 | - |
| dc.identifier.issn | 0934-9723 | - |
| dc.identifier.issn | 1435-4373 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5488 | - |
| dc.description.abstract | Purpose The purpose of this study was to investigate the impact of malignancy and chemotherapy on the clinical and microbiological characteristics of Clostridium difficile infections (CDI). Methods CDI patients with a history of malignancy within 5 years were defined as the cancer group. The characteristics of the patients were compared according to the presence of malignancy. Results Of 580 patients with CDI, 159 (27.4 %) belonged to the cancer group and 421 (72.6 %) to the non-cancer group. More of the patients in the cancer group than those in the non-cancer group had been hospitalized within the prior 2 months (P < 0.001). Leukocytosis was more common in the non-cancer group (P = 0.034), while infection by PCR ribotype 017 strains was more common in the cancer group, with marginal significance (P = 0.07). Recurrence was more frequent in the cancer group (20.4 % vs. 9.5 %, P =0.005) and cancer was an independent risk factor for recurrence of CDI (OR = 2.66, 95 % CI 1.34-5.29, P =0.005). Age also contributed to the recurrence of CDI (OR = 1.03, 95 % CI 1.00-1.06, P =0.026). Conclusions Malignancy and age are independent risk factors for recurrence of CDI. Cancer patients require careful observation for recurrence after treatment of CDI. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Springer Verlag | - |
| dc.title | Impact of malignancy on Clostridium difficile infection | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1007/s10096-016-2725-6 | - |
| dc.identifier.scopusid | 2-s2.0-84979710762 | - |
| dc.identifier.wosid | 000386157300007 | - |
| dc.identifier.bibliographicCitation | European Journal of Clinical Microbiology and Infectious Diseases, v.35, no.11, pp 1771 - 1776 | - |
| dc.citation.title | European Journal of Clinical Microbiology and Infectious Diseases | - |
| dc.citation.volume | 35 | - |
| dc.citation.number | 11 | - |
| dc.citation.startPage | 1771 | - |
| dc.citation.endPage | 1776 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Infectious Diseases | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.subject.keywordPlus | ADULT ONCOLOGY PATIENTS | - |
| dc.subject.keywordPlus | RISK-FACTORS | - |
| dc.subject.keywordPlus | HEALTH-CARE | - |
| dc.subject.keywordPlus | CLINICAL CHARACTERISTICS | - |
| dc.subject.keywordPlus | CANCER-PATIENTS | - |
| dc.subject.keywordPlus | EPIDEMIOLOGY | - |
| dc.subject.keywordPlus | DIARRHEA | - |
| dc.subject.keywordPlus | DISEASE | - |
| dc.subject.keywordPlus | CHEMOTHERAPY | - |
| dc.subject.keywordPlus | BI/NAP1/027 | - |
| dc.identifier.url | https://link.springer.com/article/10.1007/s10096-016-2725-6 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
